In a laboratory in Barcelona, researchers have engineered a molecule called celiacase that does something none of its competitors have managed: it degrades gluten efficiently right in the stomach, where it matters most. For the roughly 3 million people worldwide living with celiac disease, this represents a genuine shift in what's possible—not a cure, but a meaningful tool that could finally make a gluten-free diet easier to maintain in a world built on bread, pasta, and wheat.
Celiac disease is an autoimmune condition triggered by gluten and related proteins found in cereals. When someone with celiac eats wheat, their immune system mounts a damaging inflammatory response that can cause everything from intestinal pain to malnutrition. Currently, the only treatment is strict dietary avoidance—grueling in societies where wheat dominates the food supply. Other gluten-degrading molecules exist or are in development, but they've all fallen short in one critical way: they don't work efficiently at the stomach's acidic pH of 2. Instead, they require the higher pH of the small intestine to function, which means the damage has already begun by then. Increasing their doses to compensate makes them impractical for real-world use.
The breakthrough came from an unlikely place: the digestive juices of the carnivorous plant Nepenthes ventrata. Four years ago, researchers at the Molecular Biology Institute of Barcelona (IBMB-CSIC), led by F. Xavier Gomis-Rüth, discovered that a naturally occurring enzyme called neprosin from this plant could break down the toxic gluten fragments known as gluten immunogenic peptides (GIPs). Building on that discovery, the team—working alongside collaborators at the University of Barcelona's Faculty of Pharmacy and Food Sciences, the Institute for Food Science Research, and universities in Austria and Germany—engineered celiacase, a refined version optimized for the stomach environment.
What makes celiacase different is elegantly simple: it works at pH 2. In collaboration with the stomach's natural digestive enzyme pepsin, celiacase degrades GIPs and wheat gliadin before they ever reach the small intestine, where they would normally trigger the immune system's attack. The molecule requires very low concentrations to do this effectively, a crucial advantage for any potential therapeutic use.
The research, led by Francisco J. Pérez-Cano and F. Xavier Gomis-Rüth, with co-first authors Marina Girbal-González and Arturo Rodríguez-Banqueri, was published in EMBO Molecular Medicine in May 2026, coinciding with International Celiac Disease Day. The team demonstrated through rigorous testing that celiacase is stable in the stomach's harsh acidic environment and capable of breaking down the immunogenic peptides before they can cause harm.
The researchers are careful about claims: celiacase is framed as an "adjunctive therapeutic candidate," meaning it would work alongside a gluten-free diet, not replace it. Still, for people navigating a world where hidden gluten lurks in processed foods, sauces, and cross-contaminated kitchen surfaces, having an additional layer of protection could be transformative. The next step will be clinical trials to test safety and efficacy in humans—work that's already underway in the Barcelona lab, where a simple molecule derived from a carnivorous plant is offering celiac sufferers something they've never had before: real hope for a less restrictive future.